For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Davunetide (NAP, AL-108, CP201) is a synthetic octapeptide (NAPVSIPQ) derived from activity-dependent neuroprotective protein (ADNP). It promotes microtubule stability and inhibits tau hyperphosphorylation. The largest human trial, Boxer et al. (2014, Lancet Neurology), was a well-powered Phase 2/3 RCT in 313 PSP patients at 48 international centers that was fully negative on all primary, secondary, and exploratory endpoints. The trial authors concluded: davunetide is not an effective treatment for PSP. A Phase 2a MCI signal exists only as a conference abstract. Post-hoc sex-stratified re-analyses of the failed PSP trial, conducted by the compound's inventor, are hypothesis-generating only.
The most important fact about davunetide is that its single well-powered clinical trial was fully negative. Boxer et al. (2014, Lancet Neurology) enrolled 313 patients with progressive supranuclear palsy (PSP) -- a pure tauopathy and the indication most mechanistically suited to davunetide's tau-directed mechanism -- at 48 centers across six countries. The trial was prospectively powered, adequately complied with (94% mean medication compliance), and ran for 52 weeks. Both co-primary endpoints (PSPRS p=0.41, SEADL p=0.92), all secondary endpoints, and all exploratory endpoints were null. The trial authors' own conclusion, published in Lancet Neurology, was unambiguous: davunetide is not an effective treatment for PSP.
This result halted clinical development entirely. Allon Therapeutics, the developing company, became insolvent and was acquired by Paladin Labs in July 2013 before results were published. The concurrent FTLD/CBS/PSP safety and biomarker trial (NCT01056965) halted enrollment following the negative result. No new investigational new drug application or clinical trial for davunetide has been registered since.
Two post-hoc re-analyses of the same failed trial's dataset, published in Translational Psychiatry in 2023 and 2024 by Professor Ilana Gozes -- who invented davunetide, holds patents on it, and is disclosed as VP Drug Development at ExoNavis Therapeutics, the current license holder -- claimed sex-dependent efficacy in women. These analyses are hypothesis-generating at best. They are post-hoc, conducted by the compound's inventor with documented financial interest in the outcome, and were not pre-specified in the original trial design. They do not overturn the pre-specified ITT analysis, which was negative. The Signal presents both findings with their appropriate weight.
Davunetide was identified by Professor Ilana Gozes at Tel Aviv University as a fragment of activity-dependent neuroprotective protein (ADNP), a growth factor secreted by glial cells in response to vasoactive intestinal peptide (VIP). ADNP is one of the most highly expressed neuroprotective proteins in the brain and is essential for normal neural development. Gozes identified NAPVSIPQ -- an eight-amino-acid fragment spanning residues within ADNP's neuroprotective domain -- as the minimally active sequence responsible for ADNP's neuroprotective effects in cell culture and rodent models.
The compound was licensed to Allon Therapeutics, a Vancouver-based pharmaceutical company, which developed intranasal (AL-108) and intravenous (AL-208) formulations. Allon conducted a Phase 2a MCI trial, a Phase 2 schizophrenia trial, a Phase 2 IV trial in post-coronary bypass cognitive impairment, and ultimately the Phase 2/3 PSP trial. Allon became insolvent in mid-2013, shortly before the PSP trial results were published. Paladin Labs (Montreal) acquired Allon in 2013; Paladin was subsequently acquired by Endo International in 2014. The davunetide program was discontinued. Current development rights are held by ExoNavis Therapeutics, a Tel Aviv company associated with Professor Gozes, which has announced intent to develop CP201 (davunetide) but has not registered any active clinical trial as of early 2026.
The scientific premise for davunetide remains coherent: microtubule dysfunction and tau hyperphosphorylation are central pathological features of PSP, corticobasal degeneration, frontotemporal dementia, and Alzheimer's disease. ADNP deficiency causes tauopathy in mice that is rescued by NAP. The translation from this animal model to human trial failed, a pattern common across tauopathy drug development.
Davunetide promotes microtubule stability through interaction with the microtubule end-binding protein EB3 and through direct modulation of tubulin dynamics. ADNP contains a SxIP motif that binds EB proteins at microtubule plus-ends; the NAP fragment retains this binding capacity and promotes stable microtubule polymerization. In cells expressing mutant or deficient ADNP, NAP treatment rescues microtubule assembly defects and restores axonal transport.
Tau hyperphosphorylation inhibition is the second major proposed mechanism. Davunetide modulates GSK3-beta activity through PI3K/AKT and WNT/beta-catenin signaling pathways. In rodent models, NAP reduces phosphorylation of tau at pathological epitopes (Ser202, Thr231) and reduces neurofibrillary tangle pathology. In pure tauopathy mouse models, davunetide improved behavioral outcomes, increased heat-stable (microtubule-bound) tau, and reduced Ser202 phosphorylation.
The armadillo domain of beta-catenin binds the NAPVSIPQ sequence, placing davunetide within the WNT signaling network. This connection links davunetide to broader developmental and synaptic plasticity pathways beyond its direct microtubule effects.
A critical gap in the PSP trial was the absence of any target engagement biomarker. The Boxer 2014 trial included no measure confirming that davunetide reached its CNS target, reduced tau phosphorylation, or stabilized microtubules in treated patients. Without target engagement data, the negative clinical result cannot distinguish between insufficient brain exposure, incorrect target hypothesis, or wrong dose. This is a design limitation that leaves the mechanism question open even as the clinical question is settled.
The Boxer 2014 trial is the definitive human evidence for davunetide. PSP is a pure 4-repeat tauopathy with no amyloid pathology -- the disease most mechanistically aligned with davunetide's tau-directed mechanism. The trial was conducted at scale across six countries with high compliance and adequate power.
Both co-primary endpoints were null. PSPRS change from baseline: median 11.8 (95% CI 10.5 to 13.0) in the davunetide group vs. 11.8 (10.5 to 13.0) in placebo; p=0.41. SEADL change: -0.20 (-0.20 to -0.17) vs. -0.20 (-0.22 to -0.17); p=0.92. Secondary endpoints (Clinical Global Impression of Change, brain volumetric MRI) were negative. All exploratory cognitive and biomarker endpoints were negative. The trial authors concluded: 'Davunetide is not an effective treatment for PSP.'
The adequacy of the trial's power was confirmed by the observation that disease progression rates in both groups matched historical expectations, validating that the study was large enough to detect a real effect had one existed. The trial also generated a valuable PSP natural history dataset that has since been used in multiple secondary analyses on PSP disease progression and concomitant medication effects.
This is the strongest human evidence for davunetide, and it is fully negative. The trial was adequately powered, multi-center, international, GCP-compliant, published in Lancet Neurology, and negative on every endpoint including exploratory ones. The compound's inventor's claim that this trial 'significantly slowed disease progression in women' is a post-hoc, non-pre-specified subgroup analysis from a conflicted source -- it does not change the ITT result.
Gozes et al. (2023) re-analyzed the Boxer 2014 PSP dataset separately by sex and claimed that davunetide slowed disease progression in women specifically. Women deteriorated faster than men on the primary endpoints starting at week 13 (p=0.01). In davunetide-treated women, SEADL decline was significantly slower than in placebo-treated women at week 39 (p=0.008), and bulbar and limb motor PSPRS domains showed protection at week 52 (p=0.01). Ventricular volume increase correlated with disease severity in placebo-treated women but not in davunetide-treated women.
Gozes et al. (2024) extended this to the MCI trial dataset, claiming dose-dependent improvements in delayed visual matching in men and semantic working memory improvements at high dose in women, with a low-dose placebo effect in women at the low dose.
These findings must be contextualized clearly. Post-hoc subgroup analyses not pre-specified in the original protocol are hypothesis-generating by definition. The PSP trial was not powered to detect sex-specific effects. The analyses were conducted by the compound's inventor, who holds financial interest in a positive outcome through ExoNavis Therapeutics. The finding that women deteriorated faster overall (a baseline biological difference) creates a larger numerical gap that davunetide could appear to narrow without a true drug effect. These analyses warrant a prospectively designed, pre-specified sex-stratified trial -- they do not constitute evidence of efficacy on their own.
The post-hoc sex analyses are methodologically problematic and come from a conflicted source. They do not rescue the negative ITT result of the original trial. They are hypothesis-generating and should be interpreted as such. A pre-specified, adequately powered sex-stratified trial would be required to confirm these signals. No such trial has been registered.
The MCI Phase 2a trial (NCT00422981) enrolled 144 patients with amnestic MCI and tested 5 mg/day or 15 mg twice-daily davunetide versus placebo for 12 weeks. Reported results from conference presentations indicated improvement on some cognitive measures. However, the primary peer-reviewed publication of this trial's results has never appeared in the scientific literature. The evidence base for this indication is a conference abstract from 2008, not a published primary paper.
The subsequent post-hoc sex analysis of this dataset (Gozes et al., 2024) was published in a peer-reviewed journal but is a secondary analysis of data that itself was never fully published. The cognitive measures showing improvement differ by sex in the re-analysis (delayed visual matching in men, semantic working memory in women at high dose), which is a pattern that complicates interpretation further.
Amnestic MCI is typically prodromal Alzheimer's disease and involves mixed amyloid and tau pathology. Davunetide's mechanism targets tau specifically. The MCI signal, even if confirmed by a primary publication, would represent activity in a less mechanistically clean indication than PSP.
A conference abstract from 2008 showing some cognitive signal in 144 MCI patients is hypothesis-generating but far below the evidence level needed to conclude efficacy. The absence of a peer-reviewed primary publication of this trial 16 years after completion is a significant gap. The MCI signal does not rescue the failed PSP trial.
Javitt et al. (2012) reported that davunetide protected functional capacity in schizophrenia patients in a Phase 2 trial. Schizophrenia has been proposed as a neurodevelopmental tauopathy with tau-related axonal and synaptic dysfunction; davunetide's microtubule-stabilizing mechanism was the therapeutic rationale. The published paper reported a positive functional capacity signal, though the effect on cognitive measures was more mixed. This trial was not advanced to Phase 3.
The AL-208 IV formulation was tested in 234 patients undergoing coronary artery bypass surgery, where post-operative cognitive impairment (POCD) is a common complication thought to involve neuroinflammation and tau pathology. A single 300 mg IV dose was studied. The company press release stated the trial demonstrated safety and tolerability; no peer-reviewed efficacy data was published. This program was discontinued with Allon's insolvency.
Both of these signals represent programs that were advancing but were terminated by Allon's corporate failure rather than by negative efficacy data. They do not confirm efficacy but they also were not definitively ruled out as the PSP indication was.
The schizophrenia Phase 2 showed a functional capacity signal; the CABG trial showed only safety data publicly. Neither was advanced. Both were terminated by corporate insolvency rather than negative trial results. They represent incompletely characterized signals that cannot be interpreted as efficacy evidence without Phase 3 data.
ADNP syndrome is a rare neurodevelopmental disorder caused by de novo mutations in the ADNP gene, resulting in intellectual disability and autism spectrum disorder features in approximately 1 in 20,000 births. Because davunetide is derived from ADNP and proposed to compensate for ADNP deficiency, this indication has the strongest biological rationale of any davunetide application -- it is a true replacement therapy for a defined genetic deficiency.
Professor Gozes's ExoNavis Therapeutics has announced development of CP201 (davunetide) for ADNP syndrome. ALZFORUM lists this as Phase 3 status, but as of early 2026, no corresponding ClinicalTrials.gov registration is active. The Phase 3 claim cannot be verified through public clinical trial registries.
If a legitimate Phase 3 trial in ADNP syndrome is initiated or completed, it would represent the most scientifically coherent application of davunetide given the direct mechanistic rationale. However, the pattern established by previous programs -- promising preclinical rationale, clinical failure or incomplete development -- warrants calibrated expectations.
ADNP syndrome is the most scientifically compelling remaining application for davunetide. The genetic rationale is cleaner than any tauopathy application. However, no active trial can be verified in public registries as of early 2026. This profile will be updated if an active Phase 3 trial is registered and completed.
Intranasal administration. Clinical trials used 5-30mg daily.
Davunetide has genuine human PK and dosing data from multiple trials totaling hundreds of patients. The intranasal route is well-characterized for tolerability. The compound's clinical development is effectively dormant; no active IND or clinical trial is publicly registered as of early 2026. The evidence does not support therapeutic use for any indication in the current state of the literature. The compound is not commonly stocked by research chemical vendors. Users considering it for cognitive enhancement should understand they would be self-experimenting with a compound that failed its most rigorous clinical test in the most mechanistically appropriate indication available.
Among tauopathy-directed peptides, davunetide sits alongside other failed microtubule-stabilizing strategies including epothilone D (discontinued for CNS toxicity) and TPI-287 (discontinued after anaphylactoid reactions). All shared the same preclinical rationale and clinical failure pattern. Among nootropic peptides in this database, Cerebrolysin (profile #14) has far stronger clinical evidence (multiple Phase 3 RCTs, Cochrane reviews) despite being a poorly defined mixture. Semax (profile #50) and Selank (profile #49) have Russian regulatory approvals with smaller human datasets but at least have positive signals in the studies conducted. Dihexa (profile #17) is pure Tier 4 preclinical with zero human data. Davunetide has the most rigorously conducted human trial of any nootropic-adjacent peptide in this database -- and it is fully negative.
Davunetide has an acceptable safety profile based on multiple human trials. No safety signal halted any davunetide trial; the PSP trial was stopped for futility (negative efficacy), not safety.
In the Boxer 2014 PSP trial (n=313, 52 weeks), serious adverse events were balanced between groups: 54 in the davunetide arm and 54 in placebo. Deaths were 11 in the davunetide group and 10 in placebo -- attributable to the underlying PSP disease progression rather than drug. The main drug-attributable adverse events were nasal: epistaxis (12% davunetide vs. 8% placebo), rhinorrhoea (10% vs. 5%), and nasal discomfort (10% vs. less than 1%). These effects are consistent with intranasal peptide administration and are not serious.
The Phase 2a MCI trial (n=144, 12 weeks) and schizophrenia trial reported acceptable tolerability at 5 mg/day and 15 mg twice-daily doses. The intravenous AL-208 study (n=234, single 300 mg dose) confirmed safety and tolerability at the IV formulation's studied dose.
Long-term safety beyond 52 weeks has not been formally studied. The compound has no known hormonal, cardiovascular, or immunological signals. The absence of safety concerns across multiple trials and hundreds of patients is a genuine positive in davunetide's profile, even as its efficacy case collapsed.
Davunetide is a scientifically interesting compound that failed its clinical test. The mechanism is coherent: ADNP deficiency causes tauopathy; NAP compensates; microtubule stabilization and GSK3-beta modulation reduce tau phosphorylation. The preclinical data across multiple models of tauopathy is genuinely supportive. The translation to humans did not work in the indication best suited to test it.
The Boxer 2014 Lancet Neurology trial is among the better-designed small-molecule neurology trials of its era: international, adequately powered, 52 weeks, high compliance, GCP-compliant. It was fully negative. The trial also lacked any target engagement biomarker, so it cannot determine whether the drug failed to reach the target or the target hypothesis was wrong -- a design limitation that leaves mechanistic uncertainty.
The post-hoc sex analyses from the compound's inventor are not evidence of efficacy. They are the kind of post-hoc subgroup finding that routinely appears after major trial failures. Without a pre-specified, adequately powered sex-stratified trial, they cannot be interpreted as positive results. The Signal reports them accurately because they exist and because the compound's advocate publishes them actively; the Signal also reports the methodological reasons they cannot bear the weight placed on them.
For anyone considering davunetide for cognitive enhancement or neuroprotection: the human evidence does not support efficacy for any indication. The compound has acceptable safety. The ADNP syndrome application has the strongest mechanistic rationale. Until a registered, pre-specified clinical trial produces positive results, davunetide belongs in the 'interesting failure' category of peptide research -- a useful case study in the difficulty of translating tauopathy animal models to human disease.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use